Navigation Links
Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting
Date:12/6/2007

New Product Name Also Unveiled in Ongoing Preparation for Commercial Launch

SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced that new data, including four-year follow-up data from the Company's Phase 2 clinical trial of Specifid(TM) (formerly FavId(R)), will be reported in four separate poster presentations at the American Society of Hematology (ASH) Annual Meeting, which begins Saturday in Atlanta.

On Sunday, Dr. Omer Koc of the Cleveland Clinic will present long-term follow-up data from an 89-patient Phase 2 clinical trial of Specifid following Rituxan(R) treatment. The data suggest that the administration of Specifid following Rituxan may extend progression-free survival in patients with follicular B-cell non-Hodgkin's lymphoma (NHL) compared to historical data of Rituxan alone. In particular, 40% of the treatment-naive patients in the trial (n=35) remain progression-free at four years, compared to the published literature, which shows that approximately 20% of patients treated with Rituxan alone were progression-free at three years. Most adverse events reported in the trial were of low grade, the most common of which was injection site reaction.

Dr. Koc will present a second poster on Monday investigating patients treated with Specifid following Rituxan who achieved a complete remission during this Phase 2 trial. Of the 18 patients in complete remission (nine treatment-naive and nine relapsed from or refractory to prior therapy), only six have progressed to date and one withdrew from the trial while in complete remission. The 11 remaining patients continue to be disease-free four to five years from the start of Rituxan. In addition, 16 of the patients who achieved a complete remission did so during the Specifid phase of the trial and converted as late as 33 months from the start of Rituxan.

"We continue to be encouraged by the long-term follow-up data from this trial, particularly in the treatment-naive and complete remission populations," said Richard Ghalie, M.D., Favrille's Chief Medical Officer. "These data reaffirm our confidence in our pivotal Phase 3 trial of Specifid following Rituxan, which has a high proportion of each of the populations who appear to benefit the most. We look forward to the primary endpoint data in our Phase 3 trial next summer and ultimately to advancing this important therapy to the marketplace so that it may be made broadly available to patients in need."

Additional Specifid-related posters at the ASH Annual Meeting will include:

-- A presentation by Dr. John Timmerman from the University of California,

Los Angeles on Sunday will present data comparing Id-KLH active

immunotherapy generated in insect cells (Specifid) to Id-KLH produced

in a traditional mammalian cell manufacturing process. The analysis

concludes that Id-KLH produced via insect cells results in a more

immunogenic response in a number of in vitro and in vivo assays, and

may lead to improved activity of the final Id-KLH active immunotherapy

product.

-- A presentation by Dr. David Maloney of the Fred Hutchinson Cancer

Research Center on Monday analyzing the role of Fc receptor

polymorphisms on the outcome of treatment with Rituxan followed by

Specifid. The data suggest that long-term progression-free survival

following a treatment regimen of Rituxan plus Specifid does not

correlate with inheritance of particular Fc receptor polymorphisms nor

with the production of anti-idiotypic antibody and therefore may rely

more on a cell-mediated immune response.

A copy of each poster presentation will be available on Favrille's website at http://www.favrille.com beginning on Monday.

About the Phase 3 Clinical Trial of Specifid

Favrille initiated a pivotal, double-blind, placebo controlled Phase 3 clinical trial of Specifid in patients with follicular B-cell NHL in July 2004. Patient registration was completed in January 2006 and the last of the 349 patients was randomized in June 2006. Approximately 80 percent of the patients randomized in the trial were treatment naive, with the remainder either relapsed from or refractory to prior therapy. The Company anticipates analysis of the primary endpoint for the trial, time to disease progression (TTP), no later than July 2008. The pivotal Phase 3 trial is being conducted under a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA). Favrille has also received Fast Track designation from the FDA for Specifid.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, Specifid (formerly FavId), is based upon unique genetic information extracted from a patient's tumor. Specifid is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to progress and timing of clinical trials for Specifid, including difficulties or delays in development, testing, manufacturing and marketing Specifid or Favrille's other product candidates; delays in the availability of data from Favrille's Phase 3 clinical trial; Favrille's ability to obtain marketing approval for Specifid or Favrille's other product candidates and the timing of any such approvals, including whether it will receive expedited review as a result of the Fast Track designation; Favrille's ability to demonstrate that its idiotype protein produced from insect cell lines may stimulate a more effective immune response compared to idiotype protein derived from mammalian cells; Favrille's ability to manufacture sufficient quantities of Specifid for use in clinical trials and, if Specifid receives marketing approval, for commercialization; risks associated with achieving projected operating metrics and financial performance or the anticipated number of patients using Specifid; potential delays in patient enrollment; Favrille's ability to obtain additional financing to support its operations; and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. In addition, conclusions regarding the safety and efficacy of Favrille's product candidates cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward- looking statements contained in this release as a result of new information, future events or otherwise.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Virginia Tech Report Has National Importance
2. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
3. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
4. Haemacure Reports Third Quarter 2007 Results
5. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
6. Biotech Finishes on a High in August, Burrill Report Says
7. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
8. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
9. MDS Reports Third Quarter 2007 Results
10. First New York/New Jersey Health Care Report Card Released
11. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... , ... Amir Qureshi, MD is the first physician in Arkansas to implant ... The Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for ... to introduce the most powerful SCS system and the only stretchable lead on the ...
(Date:5/26/2017)... , ... May 26, 2017 , ... ... first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical ... “We are thrilled to partner with Cupron® to provide customers with a ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... ... ... to the Cross”: the personal journey of Bob Massey and his faith in the Lord. ... and Margaret Massey. Bob Massey is small in stature but big in character. ... love for others is apparent in all of his life decisions. , “I’m in ...
(Date:5/26/2017)... ... 26, 2017 , ... Water damage to the flooring of several classrooms at ... education officials with a number of critical issues to address before students could return ... accomplished with little or no disruption to class schedules. Second, the project had to ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
(Date:5/8/2017)... -- MACRA replaces the outdated sustainable growth rate ... Black Book Research crowdsource-surveyed 8,845 physician practices from February ... for MIPS Compliance Technology is Booming ... or more clinicians seek to buy Merit-Based Incentive Payment ... of the changes, the hunt is on for the ...
(Date:5/6/2017)... May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), ... 100,000 square feet to its Welch Allyn campus. ... commitment to bring more than 100 new jobs to ... Allyn has maintained a significant presence for more than ... new positions, a large portion of which will be ...
Breaking Medicine Technology: